Antibiotics and steroids for exacerbations of COPD in primary care: compliance with Dutch guidelines

Berendina M Roede, Patrick JE Bindels, Henk J Brouwer, Paul Bresser, Corianne AJM de Borgie and Jan M Prins

ABSTRACT

Background
The Dutch College of General Practitioners’ guidelines specify that antibiotics should only be used for severe cases of chronic obstructive pulmonary disease (COPD). However, GPs tend to administer antibiotics rather than a short course of steroid treatment regardless of severity.

Aim
The aim of this study was to determine how GPs use current guidelines in treating exacerbations of COPD, in particular whether short courses of oral steroids and antibiotics are prescribed in accordance with the Dutch guidelines for COPD.

Design of study
Retrospective analysis of medical records.

Setting
Primary healthcare centres.

Method
Medical records of patients registered at four primary healthcare centres in the Netherlands were retrospectively analysed for the period March 2001–March 2003.

Results
Of 35,589 patients, 1.3% were registered as having a diagnosis of COPD. In 2 years, 47% of the patients had no exacerbation, 35% had one or two exacerbations, and 18% had three or more exacerbations. Of 536 exacerbations, GPs prescribed a short course of oral steroids in 30% of cases, antibiotics in 29%, steroids combined with an antibiotic in 23%, and no oral steroid course or antibiotic was prescribed in 18%. Prescriptions for patients with three or more exacerbations differed significantly from those for patients with one or two exacerbations.

Conclusions
Treatment is often not in accordance with current guidelines; in particular, antibiotics are prescribed more often than recommended.

Keywords
antibiotics; COPD; exacerbation; primary health care; steroids.

INTRODUCTION

Patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) can be treated with short courses of systemic corticosteroids and/or with antibiotics. Compared with placebo, a short course of systemic steroids results in a more rapid improvement in flow rate\(^1\)–\(^3\) and dyspnoea score;\(^1\)\(^,\)\(^2\) shorter hospital stay;\(^3\) and a decrease in the rate of clinical relapse.\(^1\)\(^,\)\(^4\) Antibiotic treatment appears to be of the greatest benefit to patients with severe symptoms\(^1\) and/or a low baseline flow rate.\(^1\)\(^–\)\(^4\) For mild episodes, no significant advantage of antibiotic treatment has been demonstrated.\(^1\)\(^–\)\(^4\) In a primary healthcare setting, antibiotic treatment was shown to neither accelerate recovery nor reduce the number of relapses in patients with exacerbations.\(^2\)

The Dutch College of General Practitioners has developed guidelines for the diagnosis and treatment of COPD in general practice.\(^10\) These guidelines state that in the majority of exacerbations treatment with
bronchodilators is sufficient, but if not, a course of oral steroids (30 mg for 7–10 days) should be prescribed. Antibiotics are advised only in acute severe dyspnoea where there are symptoms of clinical infection, a low baseline flow rate (forced expiratory volume in 1 second [FEV1] <30%), or insufficient recovery after 4 days. Despite wide availability of the guidelines, implementing them is a complex process and it is unclear whether it is viable to apply them in daily practice.

In the Netherlands most patients with exacerbations of COPD are treated by GPs. The aim of this study was to assess whether short courses of steroids and antibiotics are prescribed in accordance with the Dutch guidelines.

METHOD

**Patient population**

Four primary healthcare centres took part in the study. These centres participate in the GP-based continuous morbidity registration network of the Department of General Practice, Academic Medical Centre — University of Amsterdam. This network registers chronic diseases among other data in electronic medical records (EMRs). For the period March 2001 until March 2003, we retrospectively analysed EMRs of all registered patients at these four centres.

**Data collection**

Records of all patients registered with a diagnosis of COPD were retrieved from EMRs with the use of the international classification of primary care code (ICPC) R95.11 Consultations for these patients during the 2-year study period were analysed by printing and subsequently reading and coding the EMRs. Two criteria were used to assess an exacerbation of COPD:

- when ‘exacerbation’ was used by the GP as stated in the EMR; and
- when increased symptoms of COPD (cough, shortness of breath, altered sputum conditions, increased sputum production, wheezing, or illness) were explicitly mentioned in the EMR.

When patients visited their GP for an exacerbation more than once in a period of up to 3 weeks, the whole episode was considered one exacerbation. An exacerbation after full recovery from the previous exacerbation was considered a new episode, according to the GP’s description in the EMR, or when the time between two consultations at the GP practice was longer than 3 weeks. Patients who were suspected to have a diagnosis of pneumonia, based on symptoms and physical examination, were excluded.

The number of patients with exacerbations, number of exacerbations per patient, daily medication, and treatment prescribed for the exacerbation were registered. Exacerbations treated by pulmonologists after having been referred by a GP were counted separately.

**Statistical analysis**

SPSS (version) 11.5.1 was used for statistical analysis. Differences between patients groups were analysed using χ² test. Statistical significance was set at P<0.05.

RESULTS

**Characteristics of primary healthcare centres and patients**

During the 2-year study period, 35 589 patients were registered at the four primary healthcare centres. Of these patients, 458 were registered with a diagnosis of COPD (1.3%). Median age of patients with COPD was 70 years (interquartile range = 61–77 years). Daily medication for COPD was taken by 380 (84%) patients: 83 (18%) inhaled β² agonists and/or anticholinergics only and 297 (66%) inhaled corticosteroids, with or without β² agonists and/or anticholinergics. One hundred patients (22%) used N-acetylcysteine, 22 of them without inhaled corticosteroids.

A total of 572 exacerbations in 2 years were identified in 458 patients (0.62/patient/year). In 215 patients (47%) no exacerbation in 2 years occurred, 162 (35%) had one or two exacerbations, and 81 (18%) exacerbated more often (Table 1). In patients with exacerbations, there was a median of two exacerbations over 2 years (range = 1–13).

**Treatment of exacerbations**

Of the 572 exacerbations, 36 (6%) were treated by pulmonologists. In the remaining 536 exacerbations, GPs prescribed a short course of oral steroids in 161 cases (30%), antibiotics in 157 (29%), and steroids were combined with an antibiotic in 121 (23%). In 97 cases (18%) no steroid course or antibiotic was prescribed, but compliance to daily medication use was checked and/or this medication was adapted (Table 1).
Treatment was influenced by patient characteristics. Compared with patients with one or two exacerbations, patients with three or more exacerbations were prescribed significantly more steroid courses and steroids combined with antibiotics, and less antibiotics without steroids or no antibiotics or steroids ($P \leq 0.001$ in all cases). In patients younger than 70 years, antibiotics without steroids were prescribed more often than in patients over 70 years of age ($P = 0.02$) (Table 2).

Steroid courses were usually prescribed in a dose of 30 mg per os daily for 7 or 10 days. The most frequently prescribed antibiotics were amoxycillin/clavulanate (co-amoxiclav) for 7 or 10 days (34%), doxycycline for 8 days (28%), amoxycillin for 7 days (18%), and azithromycin for 3 days (12%).

**DISCUSSION**

**Summary of main findings**

In this retrospective analysis of the medical records of patients with COPD in general practice, almost half of the patients had no acute exacerbation in the 2-year study period, one-third had one or two exacerbations, and one in five patients with COPD exacerbated more often. In instances where patients had an exacerbation of COPD, GPs often did not prescribe treatment in accordance with the Dutch College of General Practitioners guidelines for COPD. Antibiotics were often prescribed (52% of the exacerbations), and in almost 30% an antibiotic was the only medication prescribed.

GPs in the four primary healthcare centres treated half of the exacerbations with steroid courses. Evidence from the literature indicates that short courses of steroids are beneficial in exacerbations of COPD, and most international guidelines advise short courses of oral steroids for patients at home. However, only the GOLD guidelines (Global Initiative for Chronic Obstructive Lung Disease) include FEV1 below 50%. The Dutch College of General Practitioners guidelines for COPD are even more restrictive by advising short courses of oral steroids in more severe exacerbations. In this sense, GPs appear to follow the Dutch guidelines.

GPs in this study prescribed antibiotics in 23% of cases combined with steroids and in 29% of the cases without steroids. The Dutch guidelines for COPD are restrictive regarding when to prescribe antibiotics for exacerbations of COPD. They are more restrictive than the international standards, which mention altered sputum characteristics as an indication for antibiotics. It is unlikely that slightly more than half of all exacerbations in the current study fulfil the criteria of the Dutch guidelines for prescribing antibiotics. The prescription of antibiotics for exacerbations of COPD in daily practice will be even higher, as exacerbations with signs of pneumonia were excluded from the study. The possibility that GPs may sometimes label an exacerbation as a pneumonia to justify prescribing antibiotics cannot be excluded.

Guidelines are there to assist GPs to treat patients using an evidence-based approach and are not a protocol that always has to be followed in a strict way. As in general practice assessing the severity of an exacerbation may be difficult in some cases, GPs may prescribe antibiotics to be on the safe side. It is unclear why antibiotics were prescribed much more frequently than indicated in the Dutch guidelines. The Dutch guidelines may be too stringent to be followed.
in daily practice; for example, GPs may suspect that withholding antibiotics may lead to hospitalisation. Alternatively, deviation from the guidelines may not be clinically justified in many cases. It is unclear whether guidelines or prescribing patterns should be changed, and further study is required.

Prescriptions in patients with one or two exacerbations differed significantly from prescriptions for patients with three or more exacerbations. Short courses of oral steroids were prescribed more frequently in patients with three or more exacerbations, and antibiotics only were prescribed less frequently. Treatment in patients with three or more exacerbations was more in accordance with the Dutch guidelines than treatment in patients having one or two exacerbations.

Limitations of the study
Analysing medical records has its limitations. Because this evaluation was conducted retrospectively, information about specific symptoms during exacerbations of COPD could not be obtained. Although all patients were registered using the ICPC code for COPD, and the diagnoses of COPD made by GPs were confirmed by spirometric testing for almost all patients, it cannot be ruled out that the study might have included some patients with asthma.

Comparison with existing literature
Research published in 1998 showed that GPs prescribe antibiotics more frequently and steroid courses less frequently than indicated by the Dutch guidelines.18 Although the Dutch guidelines have been revised several times since then, little has changed in the treatment of exacerbations of COPD in primary health care. An evaluation of the most important barriers to change is indicated.20

Implications for clinical practice
In the general population there is an association between antibiotic consumption and resistance to pathogens.15,16 Unnecessary use of antibiotics should be avoided to prevent antimicrobial resistance of pathogens. Therefore, the current authors suggest that concerted efforts should be made to fully implement the Dutch guidelines for COPD.

Funding body
The study received an unrestricted grant from ‘PICASSO for COPD’, an initiative of Pfizer, Boehringer Ingelheim and the research institute Capri (Care and Public Health Research Institute) from the University of Maastricht, the Netherlands (Project 004).

Ethics committee
As the medical records of patients were retrospectively analysed, ethical approval was not applicable to the current research.

Competing interests
The authors have stated that there are none.

REFERENCES